Top

Published in:

Open Access 01-03-2014 | Letter to the Editors

Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease

Authors: Aleksander Prejbisz, Jacek Kądziela, Jacek Lewandowski, Elżbieta Florczak, Ewa Żylińska, Mariusz Kłopotowski, Adam Witkowski, Andrzej Januszewicz

Published in: Clinical Research in Cardiology | Issue 3/2014

Excerpt

Sirs: …

Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ (2001) Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:2427–2433PubMed

Gattone VH 2nd, Siqueira TM Jr, Powell CR, Trambaugh CM, Lingeman JE, Shalhav AL (2008) Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease. Exp Biol Med (Maywood) 233:952–957CrossRef

Patel HC, Dhillon PS, Mahfoud F, Lindsay AC, Hayward C, Ernst S, Lyon AR, Rosen SD, di Mario C (2013) The biophysics of renal sympathetic denervation using radiofrequency energy. Clin Res Cardiol. [(Epub ahead of print) PubMed PMID: 24077678]

Rippy MK, Zarins D, Barman NC, Wu A, Duncan KL, Zarins CK (2011) Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety. Clin Res Cardiol 100:1095–1101PubMedCrossRef

Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 trial): a randomised controlled trial. Lancet 376:1903–1909PubMedCrossRef

Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H (2011) Sympatho-renal axis in chronic disease. Clin Res Cardiol 100:1049–1057PubMedCentralPubMedCrossRef

Shetty SV, Roberts TJ, Schlaich MP (2013) Percutaneous transluminal renal denervation: a potential treatment option for polycystic kidney disease-related pain? Int J Cardiol 162:e58–e59PubMedCrossRef

Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ (2004) Sympathetic hyperactivity in chronic kidney disease: pathogenesis, clinical relevance, and treatment. Kidney Int 65:1568–1576PubMedCrossRef

Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, Weil J, Schmidt M, Hoppe UC, Zeller T, Bauer A, Ott C, Blessing E, Sobotka PA, Krum H, Schlaich M, Esler M, Böhm M (2013) Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 128:132–140PubMedCrossRef

10.

Vogel B, Kirchberger M, Zeier M, Stoll F, Meder B, Saure D, Andrassy M, Mueller OJ, Hardt S, Schwenger V, Strothmeyer A, Katus HA, Blessing E (2013) Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol. [(Epub ahead of print) PubMed PMID: 24126436]

11.

Schmieder RE, Ruilope LM, Ott C, Mahfoud F, Böhm M (2013) Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring. J Hum Hypertens. [(Epub ahead of print) PubMed PMID: 23636009]

Title: Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease
Authors: Aleksander Prejbisz
Jacek Kądziela
Jacek Lewandowski
Elżbieta Florczak
Ewa Żylińska
Mariusz Kłopotowski
Adam Witkowski
Andrzej Januszewicz
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 3/2014
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-013-0647-1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of percutaneous renal denervation on blood pressure level and sympathetic activity in a patient with polycystic kidney disease

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2014

The effect of placebo adherence on reducing cardiovascular mortality: a meta-analysis

Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study

Impact of type 2 diabetes mellitus and glucose control on fractional flow reserve measurements in intermediate grade coronary lesions

The year in Clinical Research in Cardiology: the official Journal of the German Cardiac Society (Deutsche Gesellschaft für Kardiologie – Herz- und Kreislaufforschung)

Admission glucose, fasting glucose, HbA1c levels and the SYNTAX score in non-diabetic patients undergoing coronary angiography

Epicardial coronary artery spasm as cause of capecitabine-induced tako tsubo cardiomyopathy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page